We assessed vascular changes during atherosclerosis regression. Compensatory enlargement of coronary arteries accommodates plaque burden during atherosclerosis development. Lipid-lowering therapy has altered the natural history of coronary atherosclerosis, but the arterial changes that occur during disease regression need to be clarified. Intravascular ultrasound was performed at baseline and after ～18 months in 432 patients with coronary disease. Mean plaque, lumen, and total vessel area were computed in a 30-mm coronary segment of interest. Mean low-density lipoprotein cholesterol level was 2.4 mmol/L, and 88%of patients received statins. Overall, changes in plaque and total vessel areas were highly correlated(r=0.82, p< 0.0001). Among the 227 patients with plaque regression, the plaque area decrease was-0.58±0.54 mm2, and changes in total vessel and lumen areas were-1.02±1.10 and-0.44±0.86 mm2, respectively. The decrease in plaque area correlated better with the change in total vessel area(r=0.64, p< 0.0001) than with the change in lumen area(r=0.20, p=0.003). The relation between plaque regression and decrease in total vessel area was significantly better(p=0.019) for patients with a >40%atheroma area(r=0.72; p< 0.0001) than for those with ≤40%(r=0.48; p=0.0004). In conclusion, regression of atherosclerotic plaque is generally accompanied by a decrease in total vessel size, without an increase in luminal dimensions. This reverse vascular remodeling may be responsible for the “regression paradox,”whereby secondary prevention is associated with clinical benefits despite minimal improvement in coronary lumen dimensions. Compensatory enlargement of coronary arteries accommodates plaque burden during atherosclerosis regression. Lipid-lowering therapy has altered the natural history of coronary atherosclerosis, but the arterial changes that occur during disease regression need to be clarified. Intravascular ultrasound was Mean at-fixed lipoprotein cholesterol level was 2.4 mmol / L, and at ~ 18 months in 432 patients with coronary disease. Mean plaque, lumen, and total vessel area were calculated in a 30-mm coronary segment of interest. Overall, changes in plaque and total vessel areas were highly correlated (r = 0.82, p <0.0001). Among the 227 patients with plaque regression, the plaque area decrease was-0.58 ± 0.54 mm2, and changes in total vessel and lumen areas were-1.02 ± 1.10 and-0.44 ± 0.86 mm2, respectively. The decrease in plaque area correlated better with the change in total The relationship between plaque regression and decrease in total vessel area was significantly better (p = 0.019) for patients with (r = 0.64, p <0.0001) than with the change in lumen area a> 40% atheroma area (r = 0.72; p <0.0001) than for those with ≤40% (r = 0.48; p = 0.0004). In conclusion, regression of atherosclerotic plaque is generally accompanied by a decrease in total vessel size, without an increase in luminal dimensions. This reverse vascular remodeling may be responsible for the “regression paradox,” which secondary prevention is associated with clinical benefits despite minimal improvement in coronary lumen dimensions.